GT Biopharma Stock Price

-0.45 (-5.78%)
Upgrade to Real-Time
Afterhours (Closed)


52 Week Range


Best deals to access real time data!
Ultimate Trader (Monthly)
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Big Cap Pro
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
GT Biopharma Inc GTBP NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.45 -5.78% 7.34 18:00:06
Open Price Low Price High Price Close Price Prev Close
7.60 7.29 7.77 7.34 7.79
Bid Price Ask Price Spread News
7.14 7.77 0.63 - -
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
3,402 348,379 $ 7.52 $ 2,621,245 - 3.90 - 19.7331
Last Trade Time Type Quantity Stock Price Currency
17:30:19 1 $ 7.34 USD


Draw Mode:

GT Biopharma Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 223.74M 30.48M 23.55M $ - $ - -8.56 -1.30
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - - - 3.00%

more financials information »

GT Biopharma News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical GTBP Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week8.368.427.217.81489,032-1.02-12.2%
1 Month7.609.127.11328.18437,130-0.26-3.42%
3 Months14.5516.456.8810.05302,571-7.21-49.55%
6 Months6.6719.73316.0911.84458,9280.6710.04%
1 Year5.5019.73313.9010.34497,7841.8433.45%
3 Years5.5019.73313.9010.34497,7841.8433.45%
5 Years5.5019.73313.9010.34497,7841.8433.45%

GT Biopharma Description

GT Biopharma Inc is an immuno-oncology company operating in the United States. It is engaged in discovering, developing and commercializing novel therapeutics from its proprietary product platform in a varied range of disease areas. The company mainly develops drugs focused on the treatment of cancer. Its key drug candidates are OXS-2175, targeting the treatment of triple-negative breast cancer; OXS-4235, targets the treatment of multiple myeloma and associated osteolytic lesions; and OXS-1550, targets cancer cells expressing the CD19 receptor and CD22 receptor. Its TriKE and TetraKE platforms offer immuno-oncology products that can treat a range of hematologic malignancies, sarcoma, and solid tumors.

Your Recent History
GT Biophar..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.